ArticleTranslational cancer research2025
Prognostic chromatin remodeling signature stratifies survival outcomes in lung adenocarcinoma patients.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) remains a major contributor to global cancer mortality, necessitating better prognostic tools. While chromatin remodeling genes (CRGs) play a pivotal role in tumorigenesis, their clinical utility in LUAD prognostication is not well defined. This study aimed to develop and validate a robust prognostic signature based on CRGs expression to stratify LUAD patients and guide clinical decision-making. Methods: Integrative bioinformatics analysis was conducted using transcriptomic profiles and clinical data from The Cancer Genome Atlas-LUAD and Gene Expression Omnibus cohorts. Molecular subtyping was achieved through consensus clustering, followed by survival analysis. A least absolute shrinkage and selection operator Cox regression-derived prognostic model was developed, complemented by nomogram construction for clinical translation. Functional role of a key gene, GJB3, was investigated using Results: Three CRG-defined molecular subtypes with distinct survival patterns and clinicopathological features were identified. A prognostic model of 19 genes was established, which can divide patients into two subgroups. High-risk patients demonstrated inferior overall survival and differential chemosensitivity profiles, whereas the low-risk group was associated with a lower Tumor Immune Dysfunction and Exclusion score. The risk score emerged as an independent prognostic factor across multivariate analyses. Experimental validation revealed that GJB3 knockdown substantially attenuated malignant phenotypes in LUAD cells. Conclusions: This study presents a validated CRG-based prognostic model for LUAD. The nomogram offers a practical tool for individualized risk assessment and may guide immunotherapy strategy selection, supporting its potential for clinical translation in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.